IRVINGTON, NY--(Marketwire - January 11, 2010) - Electro-Optical Sciences, Inc. ("EOS")
(NASDAQ: MELA) today announced the appointment of Charles Stiefel to its
Board of Directors. Mr. Stiefel brings more than 25 years of experience in
the dermatology industry to the EOS Board.
"Charlie brings a wealth of experience that is particularly valuable to
Electro-Optical Sciences at this time," said Joseph V. Gulfo, MD, President
and CEO of Electro-Optical Sciences. "As we prepare for the potential
approval and launch of MelaFind, we are transitioning from an R&D-focused
organization to a commercial business. We anticipate facing business and
strategic challenges, opportunities, and decisions similar to those that
Charlie has addressed with great success time and time again in his career.
His insight will prove invaluable to EOS as we move forward with our plans
for MelaFind, our breakthrough non-invasive, point of care, computerized
system for early melanoma detection."
Mr. Stiefel served as the Chairman and CEO of Stiefel Laboratories, Inc.
from 2001 to July 2009 when he stepped down after overseeing
GlaxoSmithKline's successful acquisition of the company. He joined Stiefel
Laboratories as General Counsel in 1982 and was subsequently named
Executive Vice President and then President of the company. He had served
as a member of Stiefel Laboratories' Board of Directors since 1975. At the
time of GSK's acquisition in March of 2009, Stiefel was the largest
privately-held dermatology company in the world.
In 2003, the South Florida Dermatology Foundation awarded him the Lifetime
Achievement Award, and he was named Ernst & Young's Entrepreneur of the
Year in Health Sciences for the State of Florida in 2006. In 2007, the
American Academy of Dermatology honored him with its Distinguished Service
Mr. Stiefel earned his B.S. degree at Yale University, and was
valedictorian of his class at Albany Law School.
Mr. Stiefel's appointment is effective immediately. This additional
appointment will fill EOS' ninth and final board seat.
About Electro-Optical Sciences
Electro-Optical Sciences is a medical technology company focused on
developing MelaFind®, a non-invasive and objective computer vision system
intended to aid in the early detection of melanoma. EOS designed MelaFind®
to assist in the evaluation of pigmented skin lesions, including atypical
moles, which have one or more clinical or historical characteristics of
melanoma, before a final decision to biopsy has been rendered. MelaFind®
acquires and displays multi-spectral (from blue to near infrared) digital
images of pigmented skin lesions and uses automatic image analysis and
statistical pattern recognition to help identify lesions to be considered
for biopsy to rule out melanoma.
Although the MelaFind® PMA is subject to the FDA's expedited review
procedures, EOS cannot predict either the timing of the FDA's decision on
the PMA application or the outcome. FDA approval is required prior to
marketing MelaFind® in the United States.
For more information on EOS, visit www.eosciences.com.
This press release includes "forward-looking statements" within the meaning
of the Securities Litigation Reform Act of 1995. These statements include
but are not limited to our plans, objectives, expectations and intentions
and other statements that contain words such as "expects," "contemplates,"
"anticipates," "plans," "intends," "believes" and variations of such words
or similar expressions that predict or indicate future events or trends, or
that do not relate to historical matters. These statements are based on our
current beliefs or expectations and are inherently subject to significant
uncertainties and changes in circumstances, many of which are beyond our
control. There can be no assurance that our beliefs or expectations will be
achieved. Actual results may differ materially from our beliefs or
expectations due to economic, business, competitive, market and regulatory